Tracking a successful DLBCL assault in Phase II, MorphoSys sets out to seize quick OK for MOR208
Encouraged by a breakthrough designation at the FDA and its latest batch of upbeat data from a Phase II study of its anti-CD19 antibody MOR208, MorphoSys says it’s blazing a straight path to regulators in search of an accelerated approval.
MorphoSys execs spent a good deal of time talking to analysts yesterday about their reasons for shooting at a quick OK. The German biotech highlighted updated data demonstrating that of the 68 evaluable patients in their study for diffuse large B cell lymphoma — a popular disease target in oncology — they tracked a 49% overall response rate and a 31% complete response rate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.